866-997-4948(US-Canada Toll Free)

Diabetic Foot Ulcers Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Diabetes

No. of Pages : 104 Pages


Global Markets Directs, \'Diabetic Foot Ulcers Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers. 

Diabetic Foot Ulcers Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Foot Ulcers.
  • A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Foot Ulcers pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Foot Ulcers Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Foot Ulcers 10
Diabetic Foot Ulcers Therapeutics under Development by Companies 12
Diabetic Foot Ulcers Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Diabetic Foot Ulcers Therapeutics Products under Development by Companies 20
Diabetic Foot Ulcers Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Diabetic Foot Ulcers Therapeutics Development 23
Smith & Nephew Plc 23
Nanotherapeutics, Inc. 24
Kaken Pharmaceutical Co.,Ltd. 25
Pluristem Therapeutics Inc. 26
CytoTools AG 27
Glycotex, Inc. 28
Phage Biotechnology Corporation 29
NovaLead Pharma Pvt. Ltd. 30
GliaMed, Inc. 31
BRIDGE BIORESEARCH PLC 32
FirstString Research, Inc. 33
CoDa Therapeutics, Inc. 34
Adocia 35
EyeGene, Inc. 36
Agennix AG 37
OmegaGenesis, Inc. 38
Praxis Pharmaceuticals Inc. 39
Diabetic Foot Ulcers Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 46
GM-1485 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pexiganan acetate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
doxycycline - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
talactoferrin alfa - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GLYC-101 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DermaPro CI-05 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
VLD-02 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Fibroblast Growth Factor-1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
trafermin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Biochaperone PDGF-BB - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KUR-211 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
WH-1 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Nexagon - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DSC-127 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LL-37 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PLX Cells for Diabetic Foot Ulcer - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
isoniazid - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Autologous Circulating Fibrocytes - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Neurotensin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Granexin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
OTR-4120 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AP-102 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Nanorods Topical - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Drug For Diabetic Foot Ulcer - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SD-101 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Stem Cell Therapy For Diabetic Complications - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
EG-Decorin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Diabetic Foot Ulcers Therapeutics Drug Profile Updates 82
Diabetic Foot Ulcers Therapeutics Discontinued Products 94
Diabetic Foot Ulcers Therapeutics - Dormant Products 95
Diabetic Foot Ulcers Product Development Milestones 97
Featured News & Press Releases 97
Oct 22, 2012: Derma Sciences On Track To Begin Phase III Program With DSC127 97
Aug 22, 2012: DermaTools Biotech Successfully Completes Phase IIb Study With DermaPro 97
Jul 23, 2012: Derma Sciences Announces Issuance Of Two New US Patents For DSC127 97
Jun 27, 2012: Derma Sciences Announces Publication Of DSC127 Phase II Trial Results In Wound Repair And Regeneration 98
Jun 13, 2012: Adocia Obtains US And European Patents For BioChaperone PDGF Formulations 99
Apr 23, 2012: Adocia Reports Positive Phase II Clinical Results For the Treatment Of Diabetic Foot Ulcer 99
Mar 06, 2012: Derma Sciences\'s Meeting With FDA Supports Initiation Of Phase III Studies With DSC127 In Diabetic Foot Ulcers 100
Jan 19, 2012: Bridge BioResearch Receives Approval For Phase IIa Trial Protocol Of Isoniazide 101
Sep 01, 2011: Kuros Completes Patient Recruitment In Phase IIb Clinical Trial With KUR-211 For Diabetic Foot Ulcers 101
Aug 08, 2011: DermaTools Biotech Extends Current Phase IIb Study Of DermaPro In Europe 102

Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Table


Number of Products Under Development for Diabetic Foot Ulcers, H1 2013 10
Products under Development for Diabetic Foot Ulcers Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Smith & Nephew Plc, H1 2013 23
Nanotherapeutics, Inc., H1 2013 24
Kaken Pharmaceutical Co.,Ltd., H1 2013 25
Pluristem Therapeutics Inc., H1 2013 26
CytoTools AG, H1 2013 27
Glycotex, Inc., H1 2013 28
Phage Biotechnology Corporation, H1 2013 29
NovaLead Pharma Pvt. Ltd., H1 2013 30
GliaMed, Inc., H1 2013 31
BRIDGE BIORESEARCH PLC, H1 2013 32
FirstString Research, Inc., H1 2013 33
CoDa Therapeutics, Inc., H1 2013 34
Adocia, H1 2013 35
EyeGene, Inc., H1 2013 36
Agennix AG, H1 2013 37
OmegaGenesis, Inc., H1 2013 38
Praxis Pharmaceuticals Inc., H1 2013 39
Assessment by Monotherapy Products, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 45
Diabetic Foot Ulcers Therapeutics Drug Profile Updates 82
Diabetic Foot Ulcers Therapeutics Discontinued Products 94
Diabetic Foot Ulcers Therapeutics Dormant Products 95
Diabetic Foot Ulcers Therapeutics Dormant Products (Contd..1) 96

List of Chart


Number of Products under Development for Diabetic Foot Ulcers, H1 2013 10
Products under Development for Diabetic Foot Ulcers Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 40
Assessment by Route of Administration, H1 2013 41
Assessment by Stage and Route of Administration, H1 2013 42
Assessment by Molecule Type, H1 2013 43
Assessment by Stage and Molecule Type, H1 2013 44

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *